Business NewsPR NewsWire • BGN Technologies Licenses Polymer for Targeted Cancer Therapy to Vaxil Bio

BGN Technologies Licenses Polymer for Targeted Cancer Therapy to Vaxil Bio

BGN Technologies Licenses Polymer for Targeted Cancer Therapy to Vaxil Bio

BEER-SHEVA, Israel, Sept. 23, 2019 /PRNewswire/ -- BGN Technologies, the technology transfer company of Ben-Gurion University (BGU) of the Negev, announced today that it has entered into an exclusive worldwide license agreement with Vaxil Bio (TSX VENTURE: VXL), a biotech company focusing...

View More : https://www.prnewswire.com:443/news-releases/bgn-technologies-licenses-polymer-for-targeted-cancer-therapy-to-vaxil-bio-...
Releted News by prnewswire
Autoliv's Interim CFO to Resign Effective as of March 2020
Proton Therapy Partners Welcomes New Members to its Board of Directors
Presidential Candidate Ben Gleib Arrested at U.S. Capitol, Demanding Congress, Other Presidential Candidates Take Action To End Corruption
BGN Technologies Licenses Polymer for Targeted Cancer Therapy to Vaxil Bio
CoinAll lists Caspian (CSP), the full-stack crypto asset management platform
Specifio Secures First Patent Covering Patent Auto-Drafting Technology
BNY Mellon, SWIFT and Microsoft Turn Cloud-Based Messaging Concept into Reality During Sibos 2019 Conference